ST Pharm
ST Pharm
  • 01Who we are
  • 02Our record
  • 03Newsroom
  • 04Contact
    • En
    • Ko
ST Pharm
  • Science & Technology
    • Business Overview
    • CDMO
      • Small Molecule
      • Oligonucleotide
      • mRNA
    • CRO
      • AnaPath Research & Service
    • R&D
      • Virtual R&D
      • Global R&D
  • About
    • ST PHARM
    • Key Members
    • History
    • Global Approval
    • ST Pharm Family
    • CI
  • Public
    • PR (Public Relations)
      • News room
        • All
        • Media Focus
        • ST PHARM News
    • IR (Investor Relations)
      • Stock Information
      • IR Library
        • Disclosure Information
        • IR Materials
        • Notice
  • Careers
  • ESG
    • Overview
    • Environmental
    • Social
    • Governance
  • Sitemap
  • Contact
  • Linkedin
Public
IR Materials
  • PR (Public Relations)
    • News room
      • All
      • Media Focus
      • ST PHARM News
  • IR (Investor Relations)
    • Stock Information
    • IR Library
      • Disclosure Information
      • IR Materials
      • Notice

IR Library

  • Disclosure Information
  • IR Materials
  • Notice
[Earning Call] 2025 1st Quarter Earning Call Presentation Material/Transcript Apr 29, 2025
KIS Korea Investors Conference 2025 Feb 17, 2025
[Earning Call] 2024 4rd Quarter Earning Call Presentation Material Feb 10, 2025
[Update] IR Material based on 3Q Quarterly Report Nov 19, 2024
[IR Material] Macquarie Securities Korea NDR (Hong Kong / Singapore) Nov 1, 2024
[Earning Call] 2024 3rd Quarter Earning Call Presentation Material Nov 1, 2024
[IR Material] Korea Investment Week 2024 Sep 6, 2024
[IR Materials] mRNA Platform Technology Mar 14, 2023
[Analyst Report] 4Q review: Oligo-driven strength Feb 17, 2023
[Earnings Summary] ST PHARM 4Q. 2022 Earnings Summary Feb 17, 2023
[Presentation] ST PHARM IR Preentation (Feb. 2023) Feb 6, 2023
[Analyst Report] Fundamentals intact despite noise Jan 16, 2023
[Analyst Report] Value of mRNA platform growing Dec 16, 2022
[Analyst Report] 3Q disappoints as clients adjust production volume Nov 1, 2022
1of2
HOMEPublicIR (Investor Relations)IR LibraryIR Materials
  • Science & Technology
    • Business Overview
    • CDMO
      • Small Molecule
      • Oligonucleotide
      • mRNA
    • CRO
      • AnaPath Research & Service
    • R&D
      • Virtual R&D
      • Global R&D
  • About
    • ST PHARM
    • Key Members
    • History
    • Global Approval
    • ST Pharm Family
    • CI
  • Public
    • PR (Public Relations)
      • News room
        • All
        • Media Focus
        • ST PHARM News
    • IR (Investor Relations)
      • Stock Information
      • IR Library
        • Disclosure Information
        • IR Materials
        • Notice
  • Careers
  • ESG
    • Overview
    • Environmental
    • Social
    • Governance
  • Sitemap
  • Contact
  • Linkedin
© 2025 ST Pharm. All rights reserved.
  • Sitemap
  • Contact